Bridging to transplant and post-transplant maintenance therapy with FLT3 inhibitors in patients with relapsed or refractory FLT3 mutated acute myeloid leukemia
OBJECTIVES AND METHODS: This single-center retrospective study was performed to evaluate the safety and efficacy of FMS-like tyrosine kinase 3 (FLT3) inhibitors before and after allogeneic hematopoietic cell transplantation (HCT) in relapsed/refractory patients with FLT3-mutation positive acute myeloid leukemia (AML).
RESULTS: Ten patients who met the eligibility criteria were included. Eight of them achieved hematological remission at HCT, within a median span of 79 days (range: 43-197). In post-HCT, patients started maintenance therapy (MT; median time-to-start 79 days, range: 43-197), and the median duration of MT was 390 days (range: 67-815). Grade 3 hematological adverse events (AEs) were found in two patients, and non-hematological AEs were found in five patients. Nine patients underwent either dose reduction, discontinuation of therapy, or a switch to another FLT3 inhibitor due to AEs. Disease relapse occurred in one patient during MT. At the time of the last follow-up, seven patients are alive and disease-free, while three have died due to infection or transplant complications.
CONCLUSION: In relapsed/refractory FLT3 mutation-positive AML, the use of FLT3 inhibitors can lead to high response rates and provide a safe bridge from HCT to MT. If sufficient attention is paid to safety, this therapy is expected to prevent disease relapse even with reduced dosages.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Hematology (Amsterdam, Netherlands) - 28(2023), 1 vom: 01. Dez., Seite 2220518 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hirose, Natsuki [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.06.2023 Date Revised 06.06.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/16078454.2023.2220518 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357745701 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357745701 | ||
| 003 | DE-627 | ||
| 005 | 20231226073245.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/16078454.2023.2220518 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1192.xml |
| 035 | |a (DE-627)NLM357745701 | ||
| 035 | |a (NLM)37272552 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hirose, Natsuki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bridging to transplant and post-transplant maintenance therapy with FLT3 inhibitors in patients with relapsed or refractory FLT3 mutated acute myeloid leukemia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.06.2023 | ||
| 500 | |a Date Revised 06.06.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES AND METHODS: This single-center retrospective study was performed to evaluate the safety and efficacy of FMS-like tyrosine kinase 3 (FLT3) inhibitors before and after allogeneic hematopoietic cell transplantation (HCT) in relapsed/refractory patients with FLT3-mutation positive acute myeloid leukemia (AML) | ||
| 520 | |a RESULTS: Ten patients who met the eligibility criteria were included. Eight of them achieved hematological remission at HCT, within a median span of 79 days (range: 43-197). In post-HCT, patients started maintenance therapy (MT; median time-to-start 79 days, range: 43-197), and the median duration of MT was 390 days (range: 67-815). Grade 3 hematological adverse events (AEs) were found in two patients, and non-hematological AEs were found in five patients. Nine patients underwent either dose reduction, discontinuation of therapy, or a switch to another FLT3 inhibitor due to AEs. Disease relapse occurred in one patient during MT. At the time of the last follow-up, seven patients are alive and disease-free, while three have died due to infection or transplant complications | ||
| 520 | |a CONCLUSION: In relapsed/refractory FLT3 mutation-positive AML, the use of FLT3 inhibitors can lead to high response rates and provide a safe bridge from HCT to MT. If sufficient attention is paid to safety, this therapy is expected to prevent disease relapse even with reduced dosages | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute myeloblastic leukemia | |
| 650 | 4 | |a FLT3 inhibitors | |
| 650 | 4 | |a bridging | |
| 650 | 4 | |a maintenance therapy | |
| 650 | 4 | |a transplantation | |
| 650 | 7 | |a fms-Like Tyrosine Kinase 3 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Phenylurea Compounds |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a FLT3 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Tachibana, Takayoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Izumi, Akihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Shuku |e verfasserin |4 aut | |
| 700 | 1 | |a Tadera, Noriyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Tamai, Yotaro |e verfasserin |4 aut | |
| 700 | 1 | |a Kanamori, Heiwa |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Masatsugu |e verfasserin |4 aut | |
| 700 | 1 | |a Nakajima, Hideaki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hematology (Amsterdam, Netherlands) |d 1996 |g 28(2023), 1 vom: 01. Dez., Seite 2220518 |w (DE-627)NLM096477237 |x 1607-8454 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:1 |g day:01 |g month:12 |g pages:2220518 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/16078454.2023.2220518 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 1 |b 01 |c 12 |h 2220518 | ||